书信:血清-控制控制

Same author

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Leukemia·2024

Same author

Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019

Same author

Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry.

Internal medicine journal·2016

Same author

Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.

Journal of thrombosis and haemostasis : JTH·2015

Same author

Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab.

Thrombosis research·2015

Same author

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Bone marrow transplantation·2014

Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026

Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026

Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026

Same journal

Documenting hospice care.

Lancet (London, England)·2026

Same journal

After the wood chipper.

Lancet (London, England)·2026

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

相关实验视频

书信:血清-控制控制

相关概念视频

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database.

Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry.

Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.

Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab.

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.

相关实验视频

书信:血清-控制控制

相关概念视频

相关文章

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database.

Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry.

Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.

Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab.

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.